Huntsman, Olin file Form II application in India for merger of equals | MLex | Specialist news and analysis on legal risk and regulation

Olin (OLN) won a $788.4M U.S. Army contract for ammunition, adding ~2.2% to its annual revenue. The company's 2025 revenue was $6.8B. Analysts expect Olin's free cash flow to grow to $300M by 2027, making its stock attractive despite net debt.

Olin (OLN) and Huntsman (HUN) cleared a key US antitrust hurdle for their merger, with the HSR Act waiting period expiring. Shareholders approved the deal in August 2026. The combined entity, OlinHuntsman, aims to leverage enhanced scale and scope. Additional regulatory approvals are pending.

Olin (OLN) and Huntsman (HUN) cleared a U.S. antitrust hurdle for their all-stock merger, expected to create a $12.5B chemicals company with $400M in cost synergies. The deal, targeting 1H 2027 completion, still needs regulatory approvals. OLN shares fell 32.2% and HUN dropped 8.6% over the past year.

Olin and Huntsman announced the expiration of the Hart-Scott-Rodino waiting period for their proposed merger. Huntsman, a global chemical manufacturer, reported 2025 revenues of approximately $6 billion. The merger's completion is subject to regulatory approvals and other conditions.

Olin (OLN) and Huntsman (HUN) cleared the U.S. antitrust waiting period for their proposed merger. The milestone satisfies one closing condition, but additional regulatory approvals and customary closing conditions are still required. Olin is a chemical manufacturer and ammunition producer, while Huntsman is a diversified chemicals company with $6B in 2025 revenue.

Olin (OLN) and Huntsman (HUN) announced the expiration of the HSR Act waiting period for their proposed merger, satisfying a key closing condition. Shareholders approved the transaction, but regulatory approvals are still required. Olin is a chemical and ammunition manufacturer, while Huntsman is a diversified chemical producer with 2025 revenues of $6 billion.